We have developed a set of specialized assets for precision oncology.
MNM177 is a novel drug target linked to DNA damage response and replication stress pathways. Inhibition of MNM177 in tumors with genomic instability leads to the death of cancer cells. MNM177 was discovered in thousands of real patients’ data via our ARETEAI platform.
By analysing data from tumor genomes, the platform has identified patterns indicating the molecular pathway that the tumors with elevated replication stress are addicted to. MNM177 is the first-in-class drug target identified using such a deconvoluting approach. The MNM177 inhibitor has the potential for both combination therapy and monotherapy (as a single agent it could even surpass PARP inhibitors due to its essential role in Microhomology-Mediated End Joining (MMEJ)).
MNM177 first indication: breast.
MNM177 can be used in replication stress-high tumors.
Most tumors have an elevated level of replication stress, giving MNM177 a broad range of therapeutic indications.
PATHWAY DECONVOLUTION FROM GENOMIC PATTERNS, AI-driven drug target platform
Drug target candidates are extensively validated in our Research Laboratory.
We also develop predictive algorithms that stratify cancer patients for targeted therapies. These algorithms predict a drug response based on tumor molecular patterns.
Our proprietary platform applies AI to a tumor's dark genome to personalize therapy for every cancer patient.Our technology